干扰素、辛伐他汀和利巴韦林联用对丙肝合并高脂血症患者血脂表达及炎性.pdfVIP

干扰素、辛伐他汀和利巴韦林联用对丙肝合并高脂血症患者血

脂表达及炎性因子的影响

刘志英;牛亚辉;张萍;党殿杰;李楠楠;赵斗贵;李友生;张萍

【摘要】ObjectiveToexploretheeffectsofPEG-IFNα-2a,simvastatin

butylandribavirincombinationtreatmentonserumlipidleveland

inflammatoryfactorsinpatientswithCHCco-infectionwith

hyperlipemia.MethodsTotal240patientswithCHCco-infectionwith

hyperlipemiafromJanuary2016toDecember2017wererecruitedinthis

study.Thepatientswererandomizeddividedintomonotherapygroups

(PEG-IFNα-2agroup80cases,simavastatinbutylgroup80casesand

ribavirin80cases,respectively)andcombinationtreatmentgroup(80

cases).Theserumlipidlevelandinflammatoryfactorswerecomparedafter

48weeksoftreatment.ResultsBeforetreatment,theserumlipidleveland

inflammatoryfactorsinfourgroupsweresimilar(P0.05).After48weeksof

treatment,thelevelsofTC,TG,LDL-C,TNF-α,MMP-9,CRP,MDAwere

significantlylowerthanthosebeforethetherapy(P0.05),whileHDL-Cwas

higher(P0.05).Thelevelofindexesincombinationtreatmentgroupwere

higherthanthoseinmonotherapygroups(P0.05).ConclusionPEG-IFNα-

2a,simvastatinbutylandribavirinwouldreducetheserumlipidleveland

inflammatoryfactorsindependentlyinpatientswithCHCco-infectionwith

hyperlipemia,andthecombinationtreatmentisevenmoreeffective,itis

worthtopromoteinclinicalpractices.%目的探讨聚乙二醇干扰素α-

2a(polyethyleneglycolinterferonalpha2a,PEG-IFNα-2a)、辛伐他汀和利巴

韦林联合用药对慢性丙型肝炎(chronichepatitisC,CHC)合并高脂血症患者的血

脂表达及炎性因子的影响.方法选择本院2016年1月至2016年12月诊治的240

例慢性丙型肝炎合并高脂血症患者作为研究对象,随机分为单药治疗治疗组(PEG-

IFNα-2a组、辛伐他汀组和利巴韦林组各60例)和联合用药治疗组(60例)四组,分

析比较治疗48周后患者的血脂水平及炎性因子表达.结果治疗前,四组患者的血脂

水平和炎性因子表达差异无统计学意义(P0.05).治疗后,四组患者的总胆固醇

(totalcholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low-

densitylipoproteincholesterol,LDL-C)、肿瘤坏死因子-α(tumornecrosis

factor-α,TNF-α)、基质金属蛋白酶-9(matixmetalloproteinase-9,MMP-9)、C

反应蛋白(Creactiveprotein,CRP)和丙二醛(m